All Title Author
Keywords Abstract

PLOS ONE  2009 

Auto-Ubiquitination-Induced Degradation of MALT1-API2 Prevents BCL10 Destabilization in t(11;18)(q21;q21)-Positive MALT Lymphoma

DOI: 10.1371/journal.pone.0004822

Full-Text   Cite this paper   Add to My Lib


Background The translocation t(11;18)(q21;q21) is the most frequent chromosomal aberration associated with MALT lymphoma and results in constitutive NF-κB activity via the expression of an API2-MALT1 fusion protein. The properties of the reciprocal MALT1-API2 were never investigated as it was reported to be rarely transcribed. Principal Findings Our data indicate the presence of MALT1-API2 transcripts in the majority of t(11;18)(q21;q21)-positive MALT lymphomas. Based on the breakpoints in the MALT1 and API2 gene, the MALT1-API2 protein contains the death domain and one or both immunoglobulin-like domains of MALT1 (~90% of cases) - mediating the possible interaction with BCL10 - fused to the RING domain of API2. Here we show that this RING domain enables MALT1-API2 to function as an E3 ubiquitin ligase for BCL10, inducing its ubiquitination and proteasomal degradation in vitro. Expression of MALT1-API2 transcripts in t(11;18)(q21;q21)-positive MALT lymphomas was however not associated with a reduction of BCL10 protein levels. Conclusion As we observed MALT1-API2 to be an efficient target of its own E3 ubiquitin ligase activity, our data suggest that this inherent instability of MALT1-API2 prevents its accumulation and renders a potential effect on MALT lymphoma development via destabilization of BCL10 unlikely.


[1]  Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, et al. (1999) Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96: 35–45.
[2]  Zhang Q, Siebert R, Yan M, Hinzmann B, Cui X, et al. (1999) Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 22: 63–68.
[3]  Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, et al. (2003) T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101: 2335–2339.
[4]  Sanchez-Izquierdo D, Buchonnet G, Siebert R, Gascoyne RD, Climent J, et al. (2003) MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood 101: 4539–4546.
[5]  Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, et al. (1999) The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93: 3601–3609.
[6]  Remstein ED, Dogan A, Einerson RR, Paternoster SF, Fink SR, et al. (2006) The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 30: 1546–1553.
[7]  Isaacson PG, Du MQ (2004) MALT lymphoma: from morphology to molecules. Nat Rev Cancer 4: 644–653.
[8]  Eckelman BP, Salvesen GS (2006) The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 281: 3254–3260.
[9]  Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, et al. (2000) The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem 275: 26661–26664.
[10]  Hu S, Yang X (2003) Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J Biol Chem 278: 10055–10060.
[11]  Ruland J, Duncan GS, Wakeham A, Mak TW (2003) Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 19: 749–758.
[12]  Ruefli-Brasse AA, French DM, Dixit VM (2003) Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science 302: 1581–1584.
[13]  Ruland J, Duncan GS, Elia A, del Barco Barrantes I, Nguyen L, et al. (2001) Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell 104: 33–42.
[14]  Wang D, You Y, Case SM, McAllister-Lucas LM, Wang L, et al. (2002) A requirement for CARMA1 in TCR-induced NF-kappa B activation. Nat Immunol 3: 830–835.
[15]  Hara H, Bakal C, Wada T, Bouchard D, Rottapel R, et al. (2004) The molecular adapter Carma1 controls entry of IkappaB kinase into the central immune synapse. J Exp Med 200: 1167–1177.
[16]  Che T, You Y, Wang D, Tanner MJ, Dixit VM, et al. (2004) MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappaB activation. J Biol Chem 279: 15870–15876.
[17]  Bidere N, Snow AL, Sakai K, Zheng L, Lenardo MJ (2006) Caspase-8 regulation by direct interaction with TRAF6 in T cell receptor-induced NF-kappaB activation. Curr Biol 16: 1666–1671.
[18]  Oeckinghaus A, Wegener E, Welteke V, Ferch U, Arslan SC, et al. (2007) Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J 26: 4634–4645.
[19]  Wu CJ, Ashwell JD (2008) NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation. Proc Natl Acad Sci U S A 105: 3023–3028.
[20]  Zhou H, Wertz I, O'Rourke K, Ultsch M, Seshagiri S, et al. (2004) Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 427: 167–171.
[21]  Uren AG, O'Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, et al. (2000) Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 6: 961–967.
[22]  Lucas PC, Yonezumi M, Inohara N, McAllister-Lucas LM, Abazeed ME, et al. (2001) Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem 276: 19012–19019.
[23]  Zhou H, Du MQ, Dixit VM (2005) Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 7: 425–431.
[24]  Baens M, Fevery S, Sagaert X, Noels H, Hagens S, et al. (2006) Selective expansion of marginal zone B cells in Eμ-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res 66: 5270–5277.
[25]  Ho L, Davis RE, Conne B, Chappuis R, Berczy M, et al. (2005) MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 105: 2891–2899.
[26]  Noels H, van Loo G, Hagens S, Broeckx V, Beyaert R, et al. (2007) A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2-MALT1 fusions. J Biol Chem 282: 10180–10189.
[27]  Stoffel A, Chaurushiya M, Singh B, Levine AJ (2004) Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proc Natl Acad Sci U S A 101: 9079–9084.
[28]  Hosokawa Y, Suzuki H, Suzuki Y, Takahashi R, Seto M (2004) Antiapoptotic function of apoptosis inhibitor 2-MALT1 fusion protein involved in t(11;18)(q21;q21) mucosa-associated lymphoid tissue lymphoma. Cancer Res 64: 3452–3457.
[29]  Hu S, Du MQ, Park SM, Alcivar A, Qu L, et al. (2006) cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest 116: 174–181.
[30]  Liu H, Ye H, Dogan A, Ranaldi R, Hamoudi RA, et al. (2001) T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 98: 1182–1187.
[31]  Maes B, Demunter A, Peeters B, De Wolf-Peeters C (2002) BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression. Blood 99: 1398–1404.
[32]  Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, et al. (1999) A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18: 5785–5794.
[33]  Kalla J, Stilgenbauer S, Schaffner C, Wolf S, Ott G, et al. (2000) Heterogeneity of the API2-MALT1 gene rearrangement in MALT-type lymphoma. Leukemia 14: 1967–1974.
[34]  Motegi M, Yonezumi M, Suzuki H, Suzuki R, Hosokawa Y, et al. (2000) API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. Am J Pathol 156: 807–812.
[35]  Baens M, Steyls A, Dierlamm J, De Wolf-Peeters C, Marynen P (2000) Structure of the MLT gene and molecular characterization of the genomic breakpoint junctions in the t(11;18)(q21;q21) of marginal zone B-cell lymphomas of MALT type. Genes Chromosomes Cancer 29: 281–291.
[36]  Liu H, Hamoudi RA, Ye H, Ruskone-Fourmestraux A, Dogan A, et al. (2004) t(11;18)(q21;q21) of mucosa-associated lymphoid tissue lymphoma results from illegitimate non-homologous end joining following double strand breaks. Br J Haematol 125: 318–329.
[37]  Hosokawa Y, Suzuki H, Nakagawa M, Lee TH, Seto M (2005) API2-MALT1 fusion protein induces transcriptional activation of the API2 gene through NF-kappaB binding elements: evidence for a positive feed-back loop pathway resulting in unremitting NF-kappaB activation. Biochem Biophys Res Commun 334: 51–60.
[38]  de Boer E, Rodriguez P, Bonte E, Krijgsveld J, Katsantoni E, et al. (2003) Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and transgenic mice. Proc Natl Acad Sci U S A 100: 7480–7485.
[39]  Yang QH, Du C (2004) Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J Biol Chem 279: 16963–16970.
[40]  Park SM, Yoon JB, Lee TH (2004) Receptor interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro. FEBS Lett 566: 151–156.
[41]  Lee JS, Hong US, Lee TH, Yoon SK, Yoon JB (2004) Mass spectrometric analysis of tumor necrosis factor receptor-associated factor 1 ubiquitination mediated by cellular inhibitor of apoptosis 2. Proteomics 4: 3376–3382.
[42]  Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, et al. (2007) IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-kappaB Activation, and TNFalpha-Dependent Apoptosis. Cell 131: 669–681.
[43]  Yui D, Yoneda T, Oono K, Katayama T, Imaizumi K, et al. (2001) Interchangeable binding of Bcl10 to TRAF2 and cIAPs regulates apoptosis signaling. Oncogene 20: 4317–4323.


comments powered by Disqus

Contact Us


微信:OALib Journal